Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor

NCT04078295 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT04078295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04078295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 5, 2019
Completion date
March 31, 2027
Enrollment
125 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid neoplasms